Treatment Resistant Depression

Although psychedelic research, and the nature of psychedelics in general, has been seemingly controversial in western cultures and governments over the past 50 years, one thing that's clear is that psychedelics treat severe depression. Treatment resistant depression is so severe that typical psychopharmacological drugs, such as SSRI's, don't work. The research supporting psilocybin in treating depression has been so strong that the FDA granted it "breakthrough therapy" status. This means that the research evidence suggests the psilocybin treatment may be an enormous improvement over already available therapies, so the FDA wants to accelerate the process of development and review. This is the second time that the FDA has granted breakthrough status for psilocybin. Additionally, the FDA has granted breakthrough status for MDMA in the treatment of PTSD.

To read more: Return of the psychedelics: Psilocybin for treatment resistant depression

FDA Calls Psychedelic Psilocybin a 'Breakthrough Therapy' for Severe Depression